|
|
Upfront Briefing
FcRn had itself a morning: J&J's nipocalimab put up positive Phase 2 SLE data, while argenx and J&J kept the immunology slide deck warm elsewhere. Travere, meanwhile, reloaded its rare-kidney pipeline with a licensing pact worth up to $1.03B for Everest's oral BTK inhibitor — a China-sourced asset that keeps the COINS Act in frame. Markets, being markets, sold biotech first and asked questions later: XBI fell 4.4% even as the S&P printed a record.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
7,609.8 |
+0.1% |
+11.0% |
| Nasdaq 100 |
30,660.6 |
+0.5% |
+21.6% |
| Russell 2000 |
2,932.0 |
+0.9% |
+16.9% |
| Healthcare (XLV) |
146.4 |
(1.0%) |
(5.9%) |
| Biotech (XBI) |
127.8 |
(4.4%) |
+5.1% |
| Nasdaq Biotech (NBI) |
5,700.9 |
(3.0%) |
(0.1%) |
| Clinical Trials (BBC) |
41.7 |
(4.9%) |
+10.8% |
|
- Biotech decoupled from a record-setting tape: XBI fell 4.4%, the Nasdaq Biotech Index 3.0% and the clinical-trials index (BBC) 4.9% even as the S&P 500 closed at a record, as money rotated into chip/AI names and the sector found no fresh positive catalyst the day after ASCO wrapped (May 29–Jun 2).
- The broad tape hit records on semiconductor strength — Marvell jumped ~33% and Hewlett Packard Enterprise ~19% after Nvidia CEO Jensen Huang's comments — lifting the S&P 500 to a record 7,609.8 (+0.1%) and the Russell 2000 +0.9%, while Alphabet slid ~4% on its $80B stock-sale plan to fund AI.
- Market data: U.S. cash close Tuesday, 2 June 2026.
The Big 3
|
1
|
J&J posts positive Phase 2 nipocalimab data in SLE
|
- Nipocalimab, an FcRn therapy, met the 24-week primary endpoint in the Phase 2 JASMINE study in systemic lupus erythematosus and showed sustained activity reduction through 52 weeks.
- Why it matters: Positive Phase 2 JASMINE data de-risk nipocalimab in SLE after hitting the 24-week primary endpoint and showing durability through 52 weeks, extending the asset's franchise value beyond existing FcRn expectations. J&J also highlighted that roughly 80% of patients are autoantibody-positive, which matters for market breadth and future positioning in autoimmune disease.
- Source: PR
|
|
2
|
Travere licenses Everest's BTK inhibitor in up to $1.03B kidney deal
|
- Travere licensed ex-China rights to civorebrutinib, an oral reversible BTK inhibitor, from Everest Medicines for $112.5M upfront plus up to $1.03B in milestones across as many as five rare-kidney indications, with tiered royalties.
- Why it matters: The deal deepens Travere's rare-kidney franchise just after April's Filspari approval in FSGS, adding an oral BTK mechanism with phase 1/2 proof-of-concept in primary membranous nephropathy — reduced anti-PLA2R antibodies and proteinuria, stable kidney function through 52 weeks — and expansion potential into FSGS, IgAN and minimal change disease. It pushes Travere into a crowded IgAN/rare-kidney race alongside BAFF/APRIL players like Vera's atacicept. Risk flag: civorebrutinib is China-sourced — Everest licensed it from Sinovent/SinoMab — keeping COINS Act and single-country-data overhang in view, and Filspari itself was approved despite a negative phase 3.
- Source: Fierce Biotech
|
| 3 | Novo Nordisk launches Wegovy pill in the UAE |
- Wegovy pill, Novo Nordisk's oral obesity product, launched in the UAE as its first market outside the U.S.
- Why it matters: As the first market outside the U.S. for Wegovy pill, the UAE becomes an early test case for Novo's ex-U.S. oral obesity rollout, including physician uptake, access mechanics and partner-led distribution. For investors, the key read-through is whether Novo can turn oral semaglutide into a broader international franchise rather than a U.S.-only lifecycle extension to the injectable base.
- Source: PR
|
Everything Else that broke
- Fulcrum scrapped its sole clinical program, the PRC2 inhibitor pociredir in sickle cell disease, after the FDA flagged class-wide malignancy risk; shares fell ~51% and the company is weighing strategic alternatives. — Fierce Biotech
- Vera Therapeutics aligned with the FDA on an earlier ORIGIN 3 eGFR analysis (now Q3 2026) to support full approval of atacicept in IgA nephropathy, ahead of its 7 July 2026 PDUFA for accelerated approval. — PR
- Vaxcyte began Phase 1 testing of VAX-A1 in healthy adults for Group A Streptococcus prevention. — PR
- Nanobiotix posted a Q1 operational and cash update, keeping funding visibility in focus. — PR
- JJP Biologics reported positive interim Phase 1b data for nebaprubart in Linear IgA Disease. — PR
- argenx showed long-term efgartigimod benefit in myositis and Sjogren's disease at EULAR. — PR
- J&J shared exploratory Phase 2 data supporting nipocalimab's role in Sjögren's disease. — PR
- Kelun-Biotech unveiled first-in-human data for B7-H3 ADC SKB500 at ASCO. — PR
- DBV screened the first infant in THRIVE, its Phase 2 VIASKIN Peanut study. — PR
- Allen Institute launched a neurodegeneration push aimed at translating atlases into precision gene therapies. — BioCentury
- INVO Fertility got a Nasdaq notice over late 10-Q and 10-K filings. — PR
- Sanofi said Biogen joined accelRare in France to speed rare-disease diagnosis. — PR
Deal Flow
| BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
- Travere licensed ex-China rights to Everest Medicines' oral BTK inhibitor civorebrutinib for $112.5M upfront and up to $1.03B in milestones across up to five rare-kidney indications, plus tiered royalties. — Fierce Biotech
VC / Private Financings
- No notable VC / private financings in the last 24 hours.
IPOs / Follow-Ons
- NRx proposed an underwritten common-stock offering with an extra 15% greenshoe option. — PR
Academic Corner - A phase 1b trial found similar efficacy and engraftment for MTC01 and same-donor fecal microbiota transplant in recurrent C. difficile. — Nature Medicine
- Obexelimab lowered flare risk versus placebo in a phase 3 trial in IgG4-related disease. — NEJM
- NEJM's editorial framed obexelimab as evidence for nondepleting B-cell therapy in IgG4-related disease. — NEJM
|
That's the tape. The S&P printed a record, your XBI book printed a teaching moment — try not to revenge-trade it before lunch. — BioBucks Team.
|
|
|
